Psych Vivas · Specialty psychiatry — clinical paraphilic disorders
Paraphilic disorders (clinical) — structured clinical viva
Fellowship viva on clinical exhibitionistic disorder: interest vs disorder, risk, WFSBP ladder, ethics of drive-reduction requests.
On this page & tools
Target exams
Interpretation
Reveal interpretation
This is exhibitionistic disorder (preferred atypical interest with acts involving nonconsenting persons plus distress), with alcohol as facilitator, partner impact, and a request for extreme drive reduction. Priorities: public risk management, substance work, psychological treatment, stepped pharmacology rather than jumping straight to GnRH, and ethical framing of goals.[1][2][7]
Structured viva answer
Reveal model viva answer
1. Classification. Paraphilia = atypical interest; disorder = distress/impairment or nonconsent/harm. Exhibitionistic disorder fits acted-on exposure to unsuspecting persons with distress. Do not pathologise unrelated consensual adult diversity.[1]
2. Differential. CSBD if control failure without exhibitionistic preference; mania/psychosis disinhibition; personality/antisocial facilitation; substance-only episodes; OCD sexual obsessions (not preferred arousal).[1]
3. Risk formulation. Motivation (exhibitionistic interest) + facilitators (alcohol, opportunity on transport, possible self-regulation deficits). Assess recurrence risk, legal status, victim impact, partner safety, suicide/shame risk.[7]
4. Assessment. Permission-based history; substances; MSE; collateral; explain confidentiality limits if ongoing risk to identifiable persons; document carefully.[2][3]
5. Management ladder. Alcohol cessation plan; CBT/relapse prevention; situational control (avoid high-risk contexts while intoxicated). SSRI strategies at antidepressant-class dosing for drive/compulsivity/comorbid mood if indicated. Antiandrogens then GnRH only for severe high-risk specialist cases with monitoring — request for “kill sex drive” is not automatic indication for immediate GnRH without assessment of severity, alternatives, consent, and medical fitness.[2][3][4][5][6]
6. Monitoring and goals. Mood, behaviour logs, sexual side-effects of SSRIs; if androgen suppression used — metabolic, bone, cardiovascular, thromboembolic domains as relevant. Goals: stop nonconsensual acts, reduce urges/distress, restore function — not moral annihilation of all sexuality.[3][6]
References
- [1]Krueger RB, Reed GM, First MB, et al. Proposals for Paraphilic Disorders in the International Classification of Diseases and Related Health Problems, Eleventh Revision (ICD-11) Arch Sex Behav, 2017.PMID 28210933
- [2]Thibaut F, De La Barra F, Gordon H, et al. The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of paraphilias World J Biol Psychiatry, 2010.PMID 20459370
- [3]Thibaut F, Cosyns P, Fedoroff JP, et al. The World Federation of Societies of Biological Psychiatry (WFSBP) 2020 guidelines for the pharmacological treatment of paraphilic disorders World J Biol Psychiatry, 2020.PMID 32452729
- [4]Assumpção AA, Garcia FD, Garcia HD, et al. Pharmacologic treatment of paraphilias Psychiatr Clin North Am, 2014.PMID 24877704
- [5]Garcia FD, Thibaut F Pharmacologic treatment of sex offenders with paraphilic disorder Curr Psychiatry Rep, 2013.PMID 23572328
- [6]Turner D, Briken P Treatment of Paraphilic Disorders in Sexual Offenders or Men With a Risk of Sexual Offending With Luteinizing Hormone-Releasing Hormone Agonists: An Updated Systematic Review J Sex Med, 2018.PMID 29289377
- [7]Seto MC The Motivation-Facilitation Model of Sexual Offending Sex Abuse, 2019.PMID 28715948